In addition to BM-MSCs [51,52,53,54,55,56,57,58,59,60,61,62,63,64], cell-based therapy with the following has also been reported to have benefits for pulmonary fibrosis: iPSCs [6,7,8,9], embryonic stem cells (ESCs) [65], resident lung MSCs [66], placenta-derived cell mixture [67,68], amnion MSCs [69], umbilical cord MSCs [70], amniotic fluid stem cells [71], adipose-derived MSCs (AD-MSCs) [72,73,74,75], hematopoietic stem cells (HSCs) [76], AT2 [77,78], lung spheroid cells [79], and prominin-1/CD133(+) epithelial progenitor cells (PEPCEs) [80]. The gene discussed is PROM1; the disease is pulmonary fibrosis.